TC
LXEO icon

Truvestments Capital’s Lexeo Therapeutics LXEO Stock Holding History

Truvestments Capital’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.86K Hold
400
– – ﹤0.01% 1022
2026
Q1 		$2.3K Buy
+400
New +$2.83K ﹤0.01% 992

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Truvestments Capital's LXEO Position: Q2 2026 in Review

Truvestments Capital held its Lexeo Therapeutics (LXEO) position steady in Q2 2026 at 400 shares worth $1.86K. The position accounts for ﹤0.01% of the portfolio, ranked #1022.

Truvestments Capital first reported a position in LXEO in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.3K in Q1 2026. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Truvestments Capital held 400 shares of Lexeo Therapeutics worth $1.86K as of Q2 2026.
  • Truvestments Capital left its Lexeo Therapeutics share count unchanged in Q2 2026.
  • Lexeo Therapeutics made up ﹤0.01% of Truvestments Capital's portfolio in Q2 2026, its #1022 holding.
  • Truvestments Capital first reported a position in Lexeo Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Truvestments Capital's Lexeo Therapeutics position peaked at $2.3K in Q1 2026.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.